What is the recommended treatment regimen for hepatitis C virus infection, including options for different genotypes, cirrhosis status, prior direct‑acting antiviral failure, and renal impairment?

HCV Treatment Recommendations

For most patients with chronic hepatitis C, treat with either sofosbuvir/velpatasvir for 12 weeks or glecaprevir/pibrentasvir for 8 weeks, as these pangenotypic regimens achieve >95% cure rates across all genotypes and cirrhosis states. 1

Treatment by Genotype and Cirrhosis Status

Genotypes 1a, 1b, 2,4,5, or 6

Without Cirrhosis (Treatment-naïve or Treatment-experienced):

• Sofosbuvir/velpatasvir for 12 weeks, OR
• Glecaprevir/pibrentasvir for 8 weeks 1

With Compensated Cirrhosis (Child-Pugh A):

• Treatment-naïve: Either sofosbuvir/velpatasvir for 12 weeks OR glecaprevir/pibrentasvir for 8 weeks 1
• Treatment-experienced: Either sofosbuvir/velpatasvir for 12 weeks OR glecaprevir/pibrentasvir for 12 weeks (note the extended duration) 1

Genotype 3 (More Complex)

Without Cirrhosis:

• Treatment-naïve: Sofosbuvir/velpatasvir for 12 weeks OR glecaprevir/pibrentasvir for 8 weeks 1
• Treatment-experienced: Sofosbuvir/velpatasvir for 12 weeks OR glecaprevir/pibrentasvir for 12 weeks 1

With Compensated Cirrhosis (Child-Pugh A) - Treatment-naïve: Choose one of three options:

1. Sofosbuvir/velpatasvir + weight-based ribavirin (1,000 mg if <75 kg; 1,200 mg if ≥75 kg) for 12 weeks
2. Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks
3. Glecaprevir/pibrentasvir for 12 weeks 1

With Compensated Cirrhosis (Child-Pugh A) - Treatment-experienced:

1. Sofosbuvir/velpatasvir + weight-based ribavirin for 12 weeks
2. Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks
3. Glecaprevir/pibrentasvir for 16 weeks (note the longer duration) 1

Important caveat for genotype 3 with cirrhosis: If resistance testing shows the NS5A Y93H mutation, use sofosbuvir/velpatasvir plus ribavirin or sofosbuvir/velpatasvir/voxilaprevir. Without this mutation, sofosbuvir/velpatasvir alone for 12 weeks is sufficient 1.

Special Populations

Renal Impairment

For patients with severe renal impairment (eGFR <30 mL/min) or on dialysis:

Preferred regimens:

• Glecaprevir/pibrentasvir for 8 weeks (all genotypes, no cirrhosis or compensated cirrhosis) - This is the safest choice as it requires no dose adjustment 2
• Grazoprevir/elbasvir for 12 weeks (genotypes 1a, 1b, 4 only) 2

Alternative regimens with strong evidence:

• Sofosbuvir/velpatasvir for 12 weeks - Despite historical concerns about sofosbuvir in renal impairment, recent evidence shows 97.69% SVR rates in dialysis patients with excellent safety 3, 4
• Sofosbuvir/daclatasvir for 12-24 weeks 2

The KDIGO 2022 guidelines specifically endorse these regimens for patients with CKD stages 4-5 and those on dialysis 2. Do not avoid sofosbuvir-based regimens in dialysis patients—the data now support their use 3, 4.

Prior DAA Failure

For patients who have failed previous direct-acting antiviral therapy, use sofosbuvir/velpatasvir/voxilaprevir for 12 weeks as the rescue regimen 1. This triple combination overcomes resistance-associated substitutions that may have developed.

Decompensated Cirrhosis (Child-Pugh B or C)

The evidence indicates that sofosbuvir-based regimens without protease inhibitors are preferred, though specific recommendations are cut off in the provided text 1. Avoid glecaprevir/pibrentasvir in decompensated cirrhosis as protease inhibitors can worsen hepatic function.

Rare or Resistant Subtypes

For patients from sub-Saharan Africa, China, or South-East Asia with infrequent subtypes (1l, 4r, 3b, 3g, 6u, 6v) or those harboring multiple NS5A resistance-associated substitutions, use sofosbuvir/velpatasvir/voxilaprevir first-line rather than dual pangenotypic regimens 1.

Key Clinical Pitfalls

1. Don't extend treatment unnecessarily: Treatment-experienced patients with compensated cirrhosis need 12 weeks of glecaprevir/pibrentasvir, not 8 weeks—this is a common error 1.

2. Genotype 3 with cirrhosis requires intensification: Unlike other genotypes, genotype 3 with cirrhosis benefits from either adding ribavirin, using triple therapy, or extending duration 1.

3. Don't withhold sofosbuvir in dialysis patients: Historical package insert warnings are outdated; current evidence supports full-dose sofosbuvir use in dialysis with 96-98% SVR rates 3, 4.

4. Treatment duration matters for treatment-experienced patients: They consistently require longer durations than treatment-naïve patients across all regimens 1.

The 2020 EASL guidelines represent the most comprehensive and recent guidance for HCV treatment, providing Level A1 evidence for most recommendations 1. These pangenotypic regimens have revolutionized HCV therapy, making cure achievable in >95% of patients regardless of genotype, prior treatment, or most comorbidities 5, 6.